CD8A and neoplasm: During treatment with immune checkpoint inhibitors, tumor cells evade immune response by upregulating the surface expression of PD-L1 and releasing EVs that expose PD-L1 to suppress the function of CD8 T cells and facilitate tumor growth in vivo [71].